INTEST CORP (INTT) Earnings History
INTEST CORP - Q4 2025 EarningsBeat
EXECUTIVE SUMMARY
InTest reported a sequential improvement in revenue and gross margin for Q4 2025, driven by increased customer spending and new product contributions. However, year-over-year revenue declined due to weakness in the semiconductor and Auto/EV segments, and profitability metrics like operating income and adjusted EBITDA saw significant year-over-year decreases.
POSITIVE HIGHLIGHTS
- •
Orders increased 22.2% year-over-year to $37.5 million, driven by strength in Auto/EV, Life Sciences, Defense/Aerospace, and Safety/Security.
positive - •
Backlog at December 31, 2025, was $53.9 million, an increase of 36.4% compared to December 31, 2024.
positive - •
Gross margin expanded 350 basis points sequentially to 45.4%, driven by volume and favorable contributions from new products.
positive - •
Nearly 80% of revenue derived from non-semiconductor end markets.
neutral
CONCERNS & RISKS
- •
Revenue declined 10.3% year-over-year to $32.8 million, primarily due to decreases in Semi and Auto/EV sales.
negative - •
Operating income decreased 38.6% year-over-year to $1.3 million.
negative - •
Adjusted EBITDA decreased 27.7% year-over-year to $3.2 million, and Adjusted EBITDA margin compressed by 240 basis points to 9.7%.
negative - •
Full year 2025 revenue declined 12.9% to $113.8 million, with a net loss of $2.5 million.
negative - •
Full year 2025 Adjusted EBITDA decreased 63.5% to $4.0 million, and Adjusted EBITDA margin compressed by 480 basis points to 3.5%.
negative - •
The historically significant Semi business continues to show sluggishness.
attention
FINANCIAL METRICS
MARGIN ANALYSIS
Margin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
REVENUE BY SEGMENT — Q4 2025 2025
VISUAL OVERVIEW
DETAILED BREAKDOWN
| Segment | Current | Prior Yr | YoY | % Total |
|---|---|---|---|---|
Electronic Test | N/A | — | — | — |
Environmental Technologies | N/A | — | — | — |
Process Technologies | N/A | — | — | — |
| Total Revenue | $0.00M | — | — | 100.0% |
Segment performance shows business unit health and growth drivers.
MANAGEMENT GUIDANCE
FY 2026
Q1 2026
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
SPECIAL ITEMS & ADJUSTMENTS
Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.
MANAGEMENT COMMENTARY
Orders remained strong at $37.5 million for the fourth quarter as Auto/EV customers moved forward with new model year programs coupled with the success we are seeing with the diversification in Life Sciences.
Revenue exceeded our guidance range and rebounded in the fourth quarter, reflecting the gradual recovery in customer capital spending we saw taking shape in the middle of the year, particularly in the Industrial and Defense/Aerospace end markets.
Gross margin reached 45.4%, driven by manufacturing efficiency initiatives undertaken over the course of 2025 and a lift from sales of new products at Alfamation and Acculogic.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
OPERATIONAL METRICS
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.